A Phase I Randomized, Placebo-Controlled, Single-Blind, Multiple-Dose, Dose-Escalation Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2017
At a glance
- Drugs SRT 2104 (Primary)
- Indications Chronic obstructive pulmonary disease; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 05 Aug 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 15 Jul 2009 New trial record